Friedrich-Stolz Award

Friedrich-Stolz Award of the GDCh Division of Medicinal Chemistry

Friedrich Stolz (1860-1936)

In memory of the industrial pharmacist and drug researcher Friedrich Stolz (see e.g. Pharmazeutische Zeitung 2010, 42 ) and his forward-looking innovative strength, the Division of Medicinal Chemistry of the German Chemical Society (GDCh) and the pharmaceutical/medicinal chemistry Division of the German Pharmaceutical Society (DPhG) have been awarding since 2022 the Friedrich-Stolz Award. The award is given to an individual or team from the industrial environment in even-numbered years and to one from academia in odd-numbered years. Recognition will be given for outstanding commitment, scientific discovery or innovative technology of proven relevance that contributes to substantial therapeutic innovation or sustainable development and goes beyond early stages of research. The award includes a certificate of award, prize money of 5,000 euros donated by the Divisions , a lecture at the "Frontiers in Medicinal Chemistry" Conference and two further lectures at one university and one industrial location within Germany.

A committee consisting of six people decides on the awarding of the prize: two board members of the GDCh Division (Chair/ Deputy Chair), two board members of the DPhG Division and two "external" people; If possible, one person per group comes from the university area and one from the industry area.

Current call for proposals: Friedrich-Stolz Award 2024 (industry)

Deadline: November 30, 2023

objective
In memory of the industrial pharmacist and drug researcher Friedrich Stolz and his forward-looking innovative strength, the GDCh Division of Medicinal Chemistry and the DPhG Division Pharmaceutical/Medical Chemistry award the Friedrich-Stolz Award. The award is given to an individual or team from the industrial environment in even-numbered years and to one from academia in odd-numbered years. Recognition will be given for outstanding commitment, scientific discovery or innovative technology of proven relevance that contributes to substantial therapeutic innovation or sustainable development and goes beyond early stages of research.

The price
The award comes with a certificate of award, prize money of 5,000 euros donated by the two Divisions , a lecture at the Frontiers in Medicinal Chemistry Conference , which will take place from March 17 to 20, 2024 in Munich, and two other lectures one university and one industrial location each within Germany. The awarding of the prize is linked to participation in the FiMC; all awardees are invited to this. On request, the Divisions will also cover the travel expenses of one person each for the two additional lectures. A prize committee, which is appointed by the board of directors of the Divisions, decides on the awarding of prizes and the locations of the additional lectures.

nomination
Individuals or teams of up to three people from the industrial environment with a professional focus in Europe can be nominated. In the case of teams that also have academic members, the main actor must be from industry. Self-nominations are not possible. All nominations include the following documents:

     

  • Concise justification (max. 2 pages) why the person or the team deserves the award, including the state of the art, context, exceptional added value, possible impact on later development phases, perspectives and references,
  • CVs of the nominees (incl. email addresses) and
  • Brief description of the 5 most important publications or patents.

submission
Please send your suggestion by e-mail and summarize it in a PDF file (max. 10 pages) to the GDCh Office, attention Maike Fries.

Friedrich-Stolz Award 2023 (Academia)

On the occasion of the FiMC 2023 in Vienna, Prof. Dr. Rolf Hartmann was honored with the Friedrich-Stolz Award 2023 in recognition of his lifetime scientific achievements in the field of rational drug design .

"The excellent interdisciplinary work is based on innovative design, synthesis and mostly a complete and extensive biophysical, biochemical and pharmacological evaluation in his own working group. Due to his excellent medical-chemical work, Prof. Dr. Hartmann succeeded in developing highly active and selective inhibitors of steroid biosynthesis "The propagation and validation of four new targets opened up the development of essential drugs for the treatment of cancer and led to three successful company foundations. Equally groundbreaking is the development of pathoblockers as a new approach in the antimicrobial resistance crisis. The performance, innovative strength and successful translation show powerful way that medicinal chemistry plays a key role in the exploration of fundamental pharmacological principles and how medicinal chemistry can work for the benefit of patients."


Award Committee 2023: Dr. Ingo Hartung (external), Prof. Dr. Stefan Laufer (DPhG), Prof. Dr. Peter H. Seeberger (external; Chair ), Prof. Dr. Holger Stark (GDCh; substitute for Prof. Dr. Anna Hirsch), Dr. Franz von Nussbaum (GDChe), Prof. Dr. Bernhard Wünsch (DPhG),

No participation due to bias : Prof. Dr. Anna Hirsch (GDCh)

Friedrich-Stolz Award 2022 (Industry)

The Friedrich-Stolz Award was first awarded toProf. Dr. Joachim Mittendorf, Dr. Markus Follman and Dr. Michael Hahn (Bayer AG) in recognition of her work in discovering soluble guanylate cyclase (sGC) modulators.

"The award-winning work initially enabled the validation of sGC as a highly relevant cardiovascular target with early lead structures and the first clinical candidates. The active ingredients Riociguat and Vericiguat - both sGC stimulators - were developed based on the work of Prof. Dr. Joachim Mittendorf and Dr. Markus Follmanns successfully approved as a drug. Riociguat is now used to treat pulmonary arterial hypertension, Vericiguat for the treatment of chronic heart failure. Based on Dr. Michael Hahn's work, in addition to the sGC stimulators mentioned, sGC activators are now also in advanced clinical testing the runcaciguat as a treatment option for chronic kidney disease. The team's performance and innovative strength vividly demonstrate the key role of medicinal chemistry in the discovery of fundamental pharmacological principles and how medicinal chemistry can work for the benefit of patients."

Award Committee 2022: Prof. Dr. Anna Hirsch (GDCh), Prof. Dr. Stefan Laufer (DPhG), Prof. Dr. Christa Müller (DPhG), Prof. Dr. Peter H. Seeberger (external; Chair )

No participation due to bias : Dr. Ingo Hartung (external), Dr. Franz von Nussbaum (GDCh)

This page has been machine translated. If you have any feedback or comments please feel free to contact us.

last modified: 22.08.2023 16:29 H from Translator